Auckland Clinical Studies
ACS is a Certified Clinical Trial site with the New Zealand Medicines and Medical Devices Safety Authority (Medsafe)
Auckland Clinical Studies and QuintilesIMS Sign
Early Clinical Development Prime Site Alliance Agreement
ACS joins Christchurch Clinical Studies Trust as the first two ECD QuintilesIMS Prime Sites
Auckland, New Zealand – November 10, 2016 – Auckland Clinical Studies (ACS) this week became one of the first two early clinical development (ECD) centers to join the QuintilesIMS Prime Site program, a global network of highly qualified sites collaborating with QuintilesIMS to improve the speed, efficiency and quality of clinical research across all phases of development.
Through the agreement signed this week, ACS and QuintilesIMS will strategically collaborate to raise the efficiency and volume of ECD research conducted in New Zealand on behalf of biopharmaceutical and medical device companies. ACS has worked with QuintilesIMS for 10 years; the Prime Site alliance will take that collaboration to the next level.
“The addition of Auckland Clinical Studies as one of our first ECD Prime Sites is testament to the quality of medical research in New Zealand,” said Vice President Ashish Jain, Global Early Clinical Development, QuintilesIMS. “This alliance further strengthens our ability to meet our customers’ early clinical development needs in Asia Pacific across a wide range of therapeutic areas.”
The ultimate goal for both QuintilesIMS and ACS is to help companies develop better treatments faster and give more patients the option of participating in clinical research. ACS joins Christchurch Clinical Studies Trust (CCST) as the Prime Site program’s first two ECD centers. CCST also signed an alliance agreement with QuintilesIMS earlier this week.
ACS has access to the large patient/volunteer population in Auckland, New Zealand’s largest city, with 2 million people. It is located directly opposite Auckland’s leading tertiary referral hospital, Auckland City Hospital (ACH), and has access to a full range of medical specialties and LabPLUS, ACH’s premier medical laboratory. ACS also has access to many researchers from the Auckland School of Medicine and Auckland’s major tertiary hospitals who are keen to take part Phase I and II studies.
Supported by a robust and world leading ethical and regulatory framework in New Zealand, ACS is a world leader in early clinical development, particularly for studies requiring novel or complex designs.
QuintilesIMS is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries.
Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches.
These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes.
Professor Ed Gane receiving the 2014 Health Research Council of New Zealand’s distinguished Liley Medal
We would like to congratulate our colleague Professor Ed Gane for receiving the 2014 Health Research Council of New Zealand’s distinguished Liley Medal for demonstrating a safer, more effective treatment for people with hepatitis C virus. The Liley Medal recognises Professor Gane’s outstanding contribution to the health and medical sciences in the field of clinical hepatology. Professor Gane was the lead author on two very highly cited papers in the prestigious medical journal, New England Journal of Medicine, which showed that people could be cured of the hepatitis C virus in just 12 weeks using an antiviral treatment called sofosbuvir. A significant proportion of the research leading to this prestigious award was conducted at Auckland Clinical Studies. We would also like to use this opportunity to thank the more than 500 patients who have participated in Hepatitis C studies at ACS over the last few years and have made this outstanding progress in the treatment of this devastating disease possible.